Ophthalmology Times: New Collaboration to Enhance Eye Care Products
Collaboration Overview
Ophthalmology Times reports that Sonoma Pharmaceuticals Inc. and EMC Pharma have entered into a co-marketing agreement to roll out an expanded prescription and OTC eye care product line. The product line focuses on patented Microcyn technology, emphasizing stabilized hypochlorous acid (HOCl) solutions for various eye care applications.
Product Innovations
Among the innovative products, the Ocucyn Eyelid and Eyelash Cleanser will feature a refreshed design and improved packaging. The complete product lineup will be presented at the American Academy of Ophthalmology's annual meeting scheduled for October 18 to 21, 2024, in Chicago.
Strengthening Market Reach
Since 2021, EMC Pharma has had exclusive rights to market and distribute Sonoma's HOCl-based eye care and prescription dermatology products in the United States. This new agreement extends EMC’s rights to include the over-the-counter Ocucyn and grants Sonoma additional rights for Acuicyn Eyelid and Eyelash Cleanser—which ophthalmologists can prescribe and utilize in their clinics.
- Ocucyn: Daily eye hygiene solution for itch and irritation.
- Acuicyn: Prescription-strength formula for managing chronic eye conditions.
Customer-Centric Design
Both Ocucyn and Acuicyn utilize hypochlorous acid solutions to gently cleanse the eye area, effectively removing dirt, oil, debris, and microorganisms. The consumer-friendly packaging of Ocucyn will feature a user-friendly single-piece dispensing mechanism, promoting ease of use.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.